Erb Holger,

University / Clinic:
Research Area:


Research Topic:

Selected publications:
  Handle F, Erb H, Luef B, Höfer J, Dietrich D, Parson W, Kristiansen G, Santer F, Culig Z
SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.
Mol Cancer Res. 2016 Jun;14(6):574-85. doi: 10.1158/1541-7786.MCR-15-0495. Epub 2016 Apr 6.

  Santer F, Erb H, Oh S, Handle F, Feiersinger G, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane J, Maitland N, Klocker H, Eder I, Culig Z
Mechanistic rationale for Mcl1 inhibition during androgen deprivation therapy
Oncotarget. 2015 Mar 20;6(8):6105-22.

  Erb H, Langlechner R, Moser P, Handle F, Casneuf T, Verstraeten K, Schlick B, Schäfer G, Hall B, Sasser K, Culig Z, Santer F
IL-6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.
Endocr Relat Cancer. 2013 Aug 2.

  Höfer J, Schäfer G, Klocker H, Erb H, Mills I, Hengst L, Puhr M, Culig Z
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21.
Am J Pathol. 2012 May;180(5):2097-107. Epub 2012 Mar 23.

  Puhr M, Höfer J, Schäfer G, Erb H, Oh S, Klocker H, Heidegger I, Neuwirt H, Culig Z
Epithelial to Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and is Mediated by Reduced Expression of miR-200c and miR-205.
Am J Pathol. 2012 Oct 3. pii: S0002-9440(12)00653-0. doi: 10.1016/j.ajpath.2012.08.011

  Oh S, Erb H, Hobisch A, Santer F, Culig Z
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Endocr Relat Cancer. 2012 May 3;19(3):305-19.

  Santer F, Höschele P, Oh S, Erb H, Bouchal J, Cavarretta I, Parson W, Meyers D, Cole P, Culig Z
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Mol Cancer Ther. 2011 Sep;10(9):1644-55.